FTY720 Ameliorates Acute Ischemic Stroke in Mice by Reducing Thrombo-Inflammation but Not by Direct Neuroprotection

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Stroke

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/STROKEAHA.113.002880PMID 24029635
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Legionella Kinase LegK2 Targets the ARP2/3 Complex To Inhibit Actin Nucleation on Phagosomes and Allow Bacterial Evasion of the Late Endocytic Pathway

  2015cited by this paper
• Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature.

  2013influential reference
• Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage

  2013cited by this paper
• Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.

  2013cited by this paper
• Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model

  2013cited by this paper
• Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?

  2012influential reference
• Immune mechanisms of stroke.

  2012cited by this paper
• FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms.

  2012cited by this paper
• Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome

  2012cited by this paper
• Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis

  2012cited by this paper
• Importance of T Lymphocytes in Brain Injury, Immunodeficiency, and Recovery after Cerebral Ischemia

  2012cited by this paper
• Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke

  2012cited by this paper
• Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

  2012cited by this paper
• Subcellular localization and transcription regulatory potency of KCNIP/Calsenilin/DREAM/KChIP proteins in cultured primary cortical neurons do not provide support for their role in CRE‐dependent gene expression

  2012cited by this paper
• Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier

  2012cited by this paper
• Ischemia and reperfusion—from mechanism to translation

  2011cited by this paper
• FTY720 Reduces Post-Ischemic Brain Lymphocyte Influx but Does Not Improve Outcome in Permanent Murine Cerebral Ischemia

  2011cited by this paper
• The immunology of stroke: from mechanisms to translation

  2011cited by this paper
• Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice

  2011cited by this paper
• Ischaemic stroke: a thrombo‐inflammatory disease?

  2011cited by this paper
• Fingolimod provides long‐term protection in rodent models of cerebral ischemia

  2011influential reference
• α2-Adrenoceptors do not Mediate Neuroprotection in Acute Ischemic Stroke in Mice

  2011cited by this paper
• Combating innate inflammation: a new paradigm for acute treatment of stroke?

  2010cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

  2010cited by this paper
• Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats

  2010cited by this paper
• Deficiency of Vasodilator-Stimulated Phosphoprotein (VASP) Increases Blood-Brain-Barrier Damage and Edema Formation after Ischemic Stroke in Mice

  2010cited by this paper
• Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

  2010influential reference
• Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor.

  2010cited by this paper
• Protective Effects of Early CD4+ T Cell Reduction in Hepatic Ischemia/Reperfusion Injury

  2010cited by this paper
• Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation.

  2010cited by this paper
• FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

  2010cited by this paper
• The S1P2 receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes

  2009cited by this paper
• The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.

  2009cited by this paper
• Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.

  2009cited by this paper
• Pivotal role of cerebral interleukin-17–producing γδT cells in the delayed phase of ischemic brain injury

  2009cited by this paper
• STIM2 Regulates Capacitive Ca2+ Entry in Neurons and Plays a Key Role in Hypoxic Neuronal Cell Death

  2009cited by this paper
• The blood-brain barrier in brain homeostasis and neurological diseases.

  2009cited by this paper
• Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial.

  2009cited by this paper
• Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

  2008cited by this paper
• Central nervous system-directed effects of FTY720 (fingolimod).

  2008cited by this paper
• FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.

  2007cited by this paper
• Bench to Bedside: The Quest for Quality in Experimental Stroke Research

  2006cited by this paper
• Role of T lymphocytes and interferon-gamma in ischemic stroke.

  2006cited by this paper
• 1,026 Experimental treatments in acute stroke

  2006cited by this paper
• Role of T Lymphocytes and Interferon-γ in Ischemic Stroke

  2006cited by this paper
• Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis

  2006cited by this paper
• Central nervous system injury-induced immune deficiency syndrome

  2005cited by this paper
• Ischaemic brain oedema.

  2002cited by this paper
• Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen.

  2001cited by this paper
• Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen

  2001cited by this paper
• Inflammation and glial responses in ischemic brain lesions.

  1998cited by this paper
• Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia.

  1996cited by this paper
• Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein.

  1995cited by this paper
• Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets.

  1995cited by this paper
• Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.

  1986cited by this paper

• Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

  2026cites this paper
• Adaptive Immunity in Immunothrombosis

  2025cites this paper
• Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders

  2025cites this paper
• Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network.

  2025cites this paper
• Bioinformatics-Based Analysis of the Screening and Evaluation of Potential Targets of FTY720 for the Treatment of Non-Small Cell Lung Cancer

  2025cites this paper
• Impaired membrane lipids in ischemic stroke: a key player in inflammation and thrombosis

  2025cites this paper
• Modular assembled biomimetic nanobubbles for synergistic therapy of ischemic stroke via cascade modulation thrombo-inflammatory network

  2025cites this paper
• Drug delivery strategies for neuroprotective therapy in ischemic stroke: Application of nanotechnology

  2025cites this paper
• Sphingosine-1-Phosphate Modulation in Neurological Disorders: Insights from MS and Stroke

  2025cites this paper
• Signaling roles of sphingolipids in the ischemic brain and their potential utility as therapeutic targets.

  2024cites this paper
• Platelet Function is Independent of Sphingolipid Manipulation.

  2024cites this paper
• Development of a new cerebral ischemia reperfusion model of Mongolian gerbils and standardized evaluation system

  2024cites this paper
• The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application

  2024cites this paper
• Stroke in the Time of Circadian Medicine.

  2024cites this paper
• Relationship between thrombus vWF and NETs with clinical severity and peripheral blood immunocytes' indicators in patients with acute ischemic stroke.

  2024cites this paper
• Multi-Target and Multi-Phase Adjunctive Cerebral Protection for Acute Ischemic Stroke in the Reperfusion Era

  2024cites this paper
• Microvascular Network Remodeling in the Ischemic Mouse Brain Defined by Light Sheet Microscopy

  2024cites this paper
• Spatiotemporal sphingosine-1-phosphate receptor 3 expression within the cerebral vasculature after ischemic stroke

  2024cites this paper
• Combined Therapeutics: Future Opportunities for Co-therapy with Thrombectomy

  2023cites this paper
• Neuroinflammation and brain–peripheral interaction in ischemic stroke: A narrative review

  2023cites this paper
• The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review

  2023cites this paper
• Dimethyl Fumarate Attenuates Lymphocyte Infiltration and Reduces Infarct Size in Experimental Stroke

  2023cites this paper
• Immunologic Implications for Stroke Recovery: Unveiling the Role of the Immune System in Pathogenesis, Neurorepair, and Rehabilitation

  2023cites this paper
• Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

  2023cites this paper
• Effects of inhaled corticosteroids on brain volumetry, depression and anxiety-like behaviors in a rat model of asthma.

  2023cites this paper
• Impact of NKG2D Signaling on Natural Killer and T‐Cell Function in Cerebral Ischemia

  2023cites this paper
• Molecular profiling of the stroke-induced alterations in the cerebral microvasculature reveals promising therapeutic candidates

  2023cites this paper
• Activation of the Epac/Rap1 signaling pathway alleviates blood-brain barrier disruption and brain damage following cerebral ischemia/reperfusion injury.

  2023cites this paper
• Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod

  2022influential citation
• Sphingosine‐1‐phosphate receptor modulation improves neurogenesis and functional recovery after stroke

  2022cites this paper
• Fingolimod Does Not Reduce Infarction After Focal Cerebral Ischemia in Mice During Active or Inactive Circadian Phases

  2022cites this paper
• The transient intraluminal filament Middle Cerebral Artery Occlusion stroke model in rats. A step by step guide and technical considerations.

  2022cites this paper
• Sphingosine‐1‐phosphate receptor modulators in stroke treatment

  2022cites this paper
• Platelet lipid metabolism in vascular thrombo-inflammation.

  2022cites this paper
• Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities

  2022cites this paper
• Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications.

  2022cites this paper
• The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta‐analysis

  2022cites this paper
• Stroke risk in multiple sclerosis: a critical appraisal of the literature

  2022cites this paper
• The Pathophysiological Aspects of Cerebral Diseases

  2022cites this paper
• In vivo brain ischemia-reperfusion model induced by hypoxia-reoxygenation using zebrafish larvae.

  2021cites this paper
• USPIO‐SWI Shows Fingolimod Enhanced Alteplase Action on Angiographic Reperfusion in eMCAO Rats

  2021cites this paper
• Erb‐(IL10)2 induces abscopal antitumor effects of radiotherapy through the activation and recruitment of lymph node CD8+ T cells

  2021cites this paper
• T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights

  2021cites this paper
• Natural Killer Cells Are Present in Rag1−/− Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke

  2021cites this paper
• Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?

  2021cites this paper
• Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond

  2021cites this paper
• Emerging therapeutic targets for cerebral edema

  2021cites this paper
• Peripheral immune cells and perinatal brain injury: a double-edged sword?

  2021cites this paper
• The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia

  2021cites this paper
• Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice

  2021cites this paper
• Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage

  2021cites this paper
• Emergency Care of Patients with Acute Ischemic Stroke.

  2021cites this paper
• Effect of leukopenia induced by cyclophosphamide on the initial stage of arterial thrombosis in mice.

  2021cites this paper
• Neuroprotection Following Stroke

  2021cites this paper
• The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms

  2021cites this paper
• Autophagy is Involved in Neuroprotective Effect of Alpha7 Nicotinic Acetylcholine Receptor on Ischemic Stroke

  2021cites this paper
• Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood–Brain Barrier Damage and Inflammation

  2021cites this paper
• Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke

  2021cites this paper
• Treadmill exercise ameliorates memory deficits and hippocampal inflammation in ovalbumin-sensitized juvenile rats.

  2020cites this paper
• Pathophysiologie des Schlaganfalls

  2020cites this paper
• The S1P–S1PR Axis in Neurological Disorders—Insights into Current and Future Therapeutic Perspectives

  2020cites this paper
• Up-regulation of Sphingosine-1-phosphate Receptors and Sphingosine Kinase 1 in the Peri-ischemic Area after Transient Middle Cerebral Artery Occlusion in Mice.

  2020cites this paper
• Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization.

  2020cites this paper
• [Current status and perspectives in the development of therapeutic agents targeting post-ischemic inflammation in the acute stage of stroke].

  2020cites this paper
• Efficacy of the sphingosine-1-phosphate receptor agonist fingolimod in animal models of stroke: an updated meta-analysis

  2020cites this paper
• FTY720 Protects Against Ischemia–Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model

  2020cites this paper
• Local Leukocyte Invasion during Hyperacute Human Ischemic Stroke

  2020cites this paper
• Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging

  2020cites this paper
• Animal models of transient ischemic attack: a review

  2020cites this paper
• Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment

  2020influential citation
• Sphingosine 1-Phosphate Receptors in Cerebral Ischemia

  2020cites this paper
• Endothelial S1P1 Signaling Counteracts Infarct Expansion in Ischemic Stroke.

  2020cites this paper
• Immunomodulatory Mechanism and Potential Therapies for Perinatal Hypoxic-Ischemic Brain Damage

  2020cites this paper
• Sphingosine 1-phosphate levels in cerebrospinal fluid after subarachnoid hemorrhage

  2020cites this paper
• Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment

  2020cites this paper
• Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

  2020cites this paper
• Therapie des akuten ischämischen Schlaganfalls

  2020cites this paper
• Filling the gaps on stroke research: Focus on inflammation and immunity

  2020cites this paper
• Experimental models and plant‑based therapy for experimental cerebral ischemia (Review)

  2020cites this paper
• Sphingosine 1-Phosphate Receptors in Cerebral Ischemia

  2020cites this paper
• Immunothrombosis and thromboinflammation in host defense and disease

  2020cites this paper
• The Intra-nuclear SphK2-S1P Axis Facilitates M1-to-M2 Shift of Microglia via Suppressing HDAC1-Mediated KLF4 Deacetylation

  2019cites this paper
• tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

  2019cites this paper
• S1P1 Regulates M1/M2 Polarization toward Brain Injury after Transient Focal Cerebral Ischemia

  2019cites this paper
• Immunomodulatory Therapeutic Strategies in Stroke

  2019cites this paper
• Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

  2019cites this paper
• Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke

  2019cites this paper
• FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment

  2019cites this paper
• Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke

  2019cites this paper
• Impact of High Salt Diet on Cerebral Vascular Function and Stroke in Tff3−/−/C57BL/6N Knockout and WT (C57BL/6N) Control Mice

  2019cites this paper
• The selective sphingosine 1‐phosphate receptor 1 modulator RP101075 improves microvascular circulation after cerebrovascular thrombosis

  2019cites this paper
• The effect of age, sex and strains on the performance and outcome in animal models of stroke.

  2019cites this paper
• Thrombo-inflammation in acute ischaemic stroke — implications for treatment

  2019cites this paper
• Effect of fingolimod on oligodendrocyte maturation under prolonged cerebral hypoperfusion.

  2019cites this paper
• Mural cell-derived laminin-α5 plays a detrimental role in ischemic stroke

  2019cites this paper
• Peripheral T Cell Depletion by FTY720 Exacerbates Hypoxic-Ischemic Brain Injury in Neonatal Mice

  2018cites this paper
• The Sphingosine 1‐Phosphate Analogue FTY720 Alleviates Seizure‐induced Overexpression of P‐Glycoprotein in Rat Hippocampus

  2018cites this paper
• Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase

  2018cites this paper
• Role of Myeloid Lineage Cell Autophagy in Ischemic Brain Injury

  2018cites this paper
• Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review

  2018cites this paper